Q2 2025 Catalyst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Catalyst Pharmaceuticals Inc (CPRX) reported a record-setting quarter with total revenue reaching $146.6 million, a 19.4% increase year over year.
- The company ended the second quarter of 2025 with a strong cash position of $652.8 million, reinforcing its ability to invest strategically for long-term growth.
- FIRAPs generated net product revenue of $84.8 million in Q2 2025, showing a growth of $7.5 million compared to Q2 2024.
- Agari continues to outperform expectations, generating $27.4 million in net product revenue in Q2 2025, a 213% increase year over year.
- Catalyst Pharmaceuticals Inc (CPRX) reaffirmed its full-year 2025 revenue guidance, reflecting confidence in its growth trajectory and market demand.
- FICAA revenue decreased by 6% year over year in the second quarter of 2025, reflecting challenges from generic competition.
- The company anticipates revenue erosion from generic competition to impact FICAA performance in the second half of the year and beyond.
- Research and development expenses increased by 46% in the second quarter of 2025 compared to the same period in 2024.
- Selling, general, and administrative expenses increased, driven by increased personnel costs and the implementation of dedicated sales forces.
- The company is still awaiting a trial date in its ongoing patent litigation for FIRAPs, which adds uncertainty to its legal and financial outlook.
Greetings and welcome to the Catalyst Pharmaceuticals 2nd quarter 2025 Financial results conference call.
At this time, all participants are in listen-only mode.
A question and answer session will follow the formal presentation.
If anyone should require operator assistance during the conference, please press start and 0 on your telephone keypad.
As a reminder, this conference is being recorded.
I would now like to turn the conference over to the Chief Financial Officer, Mike Kelb. Please go ahead, sir.
Thank you.
Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's 2nd quarter 2025 financial results and business highlights.
Richard Daley, President and CEO, will lead the call today, and Jeffrey Del Carmen, our Chief Commercial Officer, and I will also present.
Additionally, Dr. Stephen Miller, our Chief Operating Officer and Chief Scientific
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
